×
About 1,505,812 results
Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.
https://doi.org/10.1056/NEJMoa1805762
The New England Journal of Medicine; Dimopoulos MA, Dytfeld D et. al.

Nov 7th, 2018 - The immunostimulatory monoclonal antibody elotuzumab plus lenalidomide and dexamethasone has been shown to be effective in patients with relapsed or refractory multiple myeloma. The immunomodulatory agent pomalidomide plus dexamethasone has been shown to be effective in patients with multiple myeloma that is refractory to lenalidomide and a proteasome inhibitor. Patients with multiple myeloma t...

Influenza and Tdap Vaccination Coverage Among Pregnant Women - United States, April 2018.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6188122
MMWR. Morbidity and Mortality Weekly Report; Kahn KE, Black CL et. al.

Sep 27th, 2018 - Vaccinating pregnant women with influenza and tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccines can reduce the risk for influenza and pertussis for themselves and their infants. The Advisory Committee on Immunization Practices (ACIP) recommends that all women who are or might be pregnant during the influenza season receive influenza vaccine, which can be adminis...

Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis.
https://doi.org/10.1056/NEJMoa1800149
The New England Journal of Medicine; Chitnis T, Arnold DL et. al.

Sep 12th, 2018 - Treatment of patients younger than 18 years of age with multiple sclerosis has not been adequately examined in randomized trials. We compared fingolimod with interferon beta-1a in this population. In this phase 3 trial, we randomly assigned patients 10 to 17 years of age with relapsing multiple sclerosis in a 1:1 ratio to receive oral fingolimod at a dose of 0.5 mg per day (0.25 mg per day for ...

Safety and Side Effects of Rifampin versus Isoniazid in Children.
https://doi.org/10.1056/NEJMoa1714284
The New England Journal of Medicine; Diallo T, Adjobimey M et. al.

Aug 1st, 2018 - The treatment of latent infection with Mycobacterium tuberculosis is important in children because of their vulnerability to life-threatening forms of tuberculosis disease. The current standard treatment - 9 months of isoniazid - has been associated with poor adherence and toxic effects, which have hampered the effectiveness of the drug. In adults, treatment with 4 months of rifampin has been s...

A Copeptin-Based Approach in the Diagnosis of Diabetes Insipidus.
https://doi.org/10.1056/NEJMoa1803760
The New England Journal of Medicine; Fenske W, Refardt J et. al.

Aug 1st, 2018 - The indirect water-deprivation test is the current reference standard for the diagnosis of diabetes insipidus. However, it is technically cumbersome to administer, and the results are often inaccurate. The current study compared the indirect water-deprivation test with direct detection of plasma copeptin, a precursor-derived surrogate of arginine vasopressin. From 2013 to 2017, we recruited 156...

Cystic Fibrosis Colorectal Cancer Screening Consensus Recommendations.
https://doi.org/10.1053/j.gastro.2017.12.012
Gastroenterology Hadjiliadis D, Khoruts A et. al.

Dec 31st, 2017 - Improved therapy has substantially increased survival of persons with cystic fibrosis (CF). But the risk of colorectal cancer (CRC) in adults with CF is 5-10 times greater compared to the general population, and 25-30 times greater in CF patients after an organ transplantation. To address this risk, the CF Foundation convened a multi-stakeholder task force to develop CRC screening recommendatio...

Five-year results of brentuximab vedotin in patients with relapsed or refractory system...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5746164
Blood Pro B, Advani R et. al.

Oct 4th, 2017 - This pivotal phase 2 study evaluated the safety and efficacy of brentuximab vedotin in patients with relapsed or refractory (R/R) systemic anaplastic large cell lymphoma (ALCL). After a median observation period of approximately 6 years from first treatment, we examined the durability of remission, progression-free survival (PFS), overall survival (OS), and safety outcomes of patients treated o...

Effectiveness of a Third Dose of MMR Vaccine for Mumps Outbreak Control.
https://doi.org/10.1056/NEJMoa1703309
The New England Journal of Medicine; Cardemil CV, Dahl RM et. al.

Sep 6th, 2017 - The effect of a third dose of the measles-mumps-rubella (MMR) vaccine in stemming a mumps outbreak is unknown. During an outbreak among vaccinated students at the University of Iowa, health officials implemented a widespread MMR vaccine campaign. We evaluated the effectiveness of a third dose for outbreak control and assessed for waning immunity. Of 20,496 university students who were enrolled ...

Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk M...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5620419
Blood Jabbour E, Short NJ et. al.

Aug 4th, 2017 - Hypomethylating agents (HMAs) improve survival in patients with higher-risk myelodysplastic syndromes (MDS) but are less well-studied in lower-risk disease. We compared the safety and efficacy of low-dose decitabine vs low-dose azacitidine in this group of patients. Adults with low- or intermediate 1-risk MDS or MDS/myeloproliferative neoplasm (MPN), including chronic myelomonocytic leukemia, a...

Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Clas...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5791843
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology; Chen R, Zinzani PL et. al.

Apr 25th, 2017 - Purpose Hodgkin Reed-Sternberg cells harbor alterations in chromosome 9p24.1, leading to overexpression of programmed death-ligand 1 (PD-L1) and PD-L2. Pembrolizumab, a programmed death 1-blocking antibody, demonstrated a high overall response rate (ORR) in patients with relapsed or refractory classic Hodgkin lymphoma (rrHL) in phase I testing. Methods KEYNOTE-087 ( ClinicalTrials.gov identifie...

Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5901965
The New England Journal of Medicine; Hochhaus A, Larson RA et. al.

Mar 8th, 2017 - Imatinib, a selective BCR-ABL1 kinase inhibitor, improved the prognosis for patients with chronic myeloid leukemia (CML). We conducted efficacy and safety analyses on the basis of more than 10 years of follow-up in patients with CML who were treated with imatinib as initial therapy. In this open-label, multicenter trial with crossover design, we randomly assigned patients with newly diagnosed C...

Late Relapse of Classical Hodgkin Lymphoma: An Analysis of the German Hodgkin Study Gro...
https://doi.org/10.1200/JCO.2016.71.3289
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology; Bröckelmann PJ, Goergen H et. al.

Feb 27th, 2017 - Purpose Clinical characteristics, therapeutic approaches, and prognosis of late relapse (LR) in patients with classic Hodgkin lymphoma (cHL) are poorly understood. We performed a comprehensive analysis of LR of Hodgkin lymphoma (LR-HL). Methods To estimate the incidence of LR-HL, we retrospectively analyzed 6,840 patients with cHL included in the German Hodgkin Study Group trials HD7 to HD12. P...

Perioperative Timing of Infliximab and the Risk of Serious Infection After Elective Hip...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5529262
Arthritis Care & Research; George MD, Baker JF et. al.

Jan 27th, 2017 - The optimal timing of tumor necrosis factor antagonists before elective surgery is unknown. This study evaluated the association between infliximab timing and serious infection after elective hip or knee arthroplasty. A retrospective cohort study evaluated US Medicare patients with rheumatoid arthritis, inflammatory bowel disease, psoriasis, psoriatic arthritis, or ankylosing spondylitis who re...

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.
https://doi.org/10.1056/NEJMoa1513257
The New England Journal of Medicine; Roberts AW, Davids MS et. al.

Dec 7th, 2015 - New treatments have improved outcomes for patients with relapsed chronic lymphocytic leukemia (CLL), but complete remissions remain uncommon. Venetoclax has a distinct mechanism of action; it targets BCL2, a protein central to the survival of CLL cells. We conducted a phase 1 dose-escalation study of daily oral venetoclax in patients with relapsed or refractory CLL or small lymphocytic lymphoma...

FDA approves first generics of Gilenya
https://www.fda.gov/news-events/press-announcements/fda-approves-first-generics-gilenya
FDA

Dec 8th, 2019 - The U.S. Food and Drug Administration has approved three applications for first generics of Gilenya (fingolimod) capsules for the treatment of relapsing forms of multiple sclerosis (MS) in adult patients.

Hereditary Cancer Syndromes and Risk Assessment ACOG COMMITTEE OPINION, Number 793
https://journals.lww.com/greenjournal/Fulltext/2019/12000/Hereditary_Cancer_Syndromes_and_Risk_Assessment_.39.aspx
Obstetrics & Gynecology; ACOG

Nov 30th, 2019 - A hereditary cancer syndrome is a genetic predisposition to certain types of cancer, often with onset at an early age, caused by inherited pathogenic variants in one or more genes. Most hereditary cancer syndromes exhibit autosomal dominant inheritance. The most common hereditary cancer syndromes related to women’s cancer include hereditary breast and ovarian cancer syndrome, Lynch syndrome, Li...

Fasting Triglycerides & Glucose Index: A Useful Screening Test for Assessing Insulin Resistance in Patients Diagnosed with Rheumatoid Arthritis & Systemic Lupus Erythematosus
https://dmsjournal.biomedcentral.com/articles/10.1186/s13098-019-0495-x
Diabetology & Metabolic Syndrome; Contreras-Haro B, et al

Nov 26th, 2019 - Insulin resistance (IR) is frequently observed in patients with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE). In clinical practice, IR assessment is limited to a low proportion of patients due to cost and equipment and technical expertise requirements. The surrogate index of triglycerides and glucose (TyG index) has been validated in non-rheumatic populations, showing adequat...

Eastern Equine Encephalitis Virus — Another Emergent Arbovirus in the United States
https://www.nejm.org/doi/full/10.1056/NEJMp1914328
New England Journal of Medicine; David M. Morens, M.D. et. al.

Nov 24th, 2019 - Humans have always lived in intimate association with arthropods that transmit pathogens between humans or from animals to humans. About 700,000 deaths due to vectorborne diseases occur globally each year, according to World Health Organization estimates. In the summer and fall of 2019, nine U.S. states have reported 36 human cases (14 of them fatal) of one of the deadliest of these diseases: e...

FDA takes second action under international collaboration, approves new treatment option for patients with chronic lymphocytic leukemia
https://www.fda.gov/news-events/press-announcements/fda-takes-second-action-under-international-collaboration-approves-new-treatment-option-patients
FDA

Nov 24th, 2019 - Today, as part of Project Orbis, a collaboration with the Australian Therapeutic Goods Administration (TGA) and Health Canada, the U.S. Food and Drug Administration granted supplemental approval to Calquence (acalabrutinib) for the treatment of adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). This new approved indication for Calquence provides a new treatment ...

Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline
https://www.atsjournals.org/doi/full/10.1164/rccm.201909-1874ST
American Journal of Respiratory and Critical Care Medicine; Payam Nahid et al

Nov 20th, 2019 - The American Thoracic Society, U.S. Centers for Disease Control and Prevention, European Respiratory Society, and Infectious Diseases Society of America jointly sponsored this new practice guideline on the treatment of drug-resistant tuberculosis (DR-TB). The document includes recommendations on the treatment of multidrug-resistant TB (MDR-TB) as well as isoniazid-resistant but rifampin-suscept...

Recent Trends in Squamous Cell Carcinoma of the Anus Incidence & Mortality in the United States, 2001-2015
https://academic.oup.com/jnci/advance-article-abstract/doi/10.1093/jnci/djz219/5622917
J National Cancer Institute; Deshmukh AA, et al

Nov 18th, 2019 - Squamous cell carcinoma of the anus (SCCA) incidence is rising in the United States (US). Study of incidence trends by stage at diagnosis, age-specific and birth cohort patterns, and trends in mortality could provide evidence for a true increase and etiological clues for this rise.

FDA approves therapy to treat patients with relapsed and refractory mantle cell lymphoma supported by clinical trial results showing high response rate of tumor shrinkage
https://www.fda.gov/news-events/press-announcements/fda-approves-therapy-treat-patients-relapsed-and-refractory-mantle-cell-lymphoma-supported-clinical
FDA

Nov 16th, 2019 - The U.S. Food and Drug Administration granted accelerated approval to Brukinsa (zanubrutinib) capsules for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy.

Diffuse large B cell lymphoma
https://www.cancertherapyadvisor.com/home/decision-support-in-medicine/hematology/diffuse-large-b-cell-lymphoma/
Cancer Therapy Advisor; Thomas M. Habermann

Nov 13th, 2019 - Diffuse large B-cell lymphoma (DLBCL) is an aggressive lymphoma that is potentially curable. DLBCL is the most common non-Hodgkin lymphoma (NHL) representing about 30% of all cases of NHL in the United States of America (USA) and Europe. There are over 76 different types of lymphoma. It is essential to establish the correct histological diagnosis prior to treatment.

NCCN Guidelines Insights: Kidney Cancer, Version 2.2020
https://jnccn.org/view/journals/jnccn/17/11/article-p1278.xml
JNCCN Motzer RJ, et al.

Nov 13th, 2019 - The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for the clinical management of patients with clear cell and non–clear cell renal cell carcinoma, and are intended to assist with clinical decision-making. These NCCN Guidelines Insights summarize the NCCN Kidney Cancer Panel discussions for the 2020 update to the guidelines regarding initial management and first-lin...

Diffuse Large B-Cell Lymphoma: ESMO Clinical Practice Guidelines
https://www.esmo.org/Guidelines/Haematological-Malignancies/Diffuse-Large-B-Cell-Lymphoma
Annals of Oncology; Tilly H et al

Nov 13th, 2019 - Diffuse large B-cell lymphoma is relatively common and represents 30%–58% of non-Hodgkin’s lymphomas. The updated ESMO Clinical Practice Guidelines provide information on the current management of diffuse large B-cell lymphoma including recommendations for screening and diagnosis, staging and risk assessment and stage-matched therapeutic strategies including specific recommendations for young a...

FDA approves first therapy to treat patients with rare blood disorder
https://www.fda.gov/news-events/press-announcements/fda-approves-first-therapy-treat-patients-rare-blood-disorder
FDA FDA

Nov 9th, 2019 - Today the U.S. Food and Drug Administration granted approval to Reblozyl (luspatercept–aamt) for the treatment of anemia (lack of red blood cells) in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions.

Diffuse Large B-Cell Lymphoma
https://www.lymphoma.org/aboutlymphoma/nhl/dlbcl/
Lymphoma Research Foundation;

Nov 6th, 2019 - Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) in the United States and worldwide, accounting for about 22 percent of newly diagnosed cases of B-cell NHL in the United States. More than 18,000 people are diagnosed with DLBCL each year.

BIOGEN AND ALKERMES ANNOUNCE FDA APPROVAL OF VUMERITY™ (DIROXIMEL FUMARATE) FOR MULTIPLE SCLEROSIS
http://investors.biogen.com/news-releases/news-release-details/biogen-and-alkermes-announce-fda-approval-vumeritytm-diroximel

Nov 5th, 2019 - Biogen Inc. (Nasdaq: BIIB) and Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) approved VUMERITY™ (diroximel fumarate), a novel oral fumarate with a distinct chemical structure, for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease...

Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis
https://www.nejm.org/doi/full/10.1056/NEJMoa1909953
The New England Journal of Medicine; Tait, D. et. al.

Oct 28th, 2019 - BACKGROUND Results of an earlier analysis of a trial of the M72/AS01E candidate vaccine against Mycobacterium tuberculosis showed that in infected adults, the vaccine provided 54.0% protection against active pulmonary tuberculosis disease, without evident safety concerns. We now report the results of the 3-year final analysis of efficacy, safety, and immunogenicity. METHODS From August 201...

FDA Approves Botox® (Onabotulinumtoxina) For Pediatric Patients With Lower Limb Spasticity, Excluding Spasticity Caused By Cerebral Palsy
https://www.allergan.com/News/Details/2019/10/FDA%20Approves%20BOTOX%20onabotulinumtoxinA%20for%20Pediatric%20Patients%20with%20Lower%20Limb%20Spasticity%20Excluding%20Sp

Oct 23rd, 2019 - Allergan plc (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) approved the company's supplemental Biologics License Application (sBLA) for BOTOX® for the treatment of pediatric patients (2 to 17 years of age) with lower limb spasticity, excluding spasticity caused by cerebral palsy (CP). This marks the 11th BOTOX® therapeutic indication, having been approved for pedi...

FDA approves niraparib for HRD-positive advanced ovarian cancer
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-niraparib-hrd-positive-advanced-ovarian-cancer

Oct 22nd, 2019 - On October 23, 2019,the Food and Drug Administration approved niraparib (ZEJULA, Tesaro, Inc.) for patients with advanced ovarian, fallopian tube, or primary peritoneal cancer treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD)-positive status. HRD is defined by either a deleterious or suspected deleterious BRCA mu...

FDA approves new breakthrough therapy for cystic fibrosis
https://www.fda.gov/news-events/press-announcements/fda-approves-new-breakthrough-therapy-cystic-fibrosis

Oct 20th, 2019 - The U.S. Food and Drug Administration today approved Trikafta (elexacaftor/ivacaftor/tezacaftor), the first triple combination therapy available to treat patients with the most common cystic fibrosis mutation. Trikafta is approved for patients 12 years and older with cystic fibrosis who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, wh...

Predicting the Risk of Postoperative Pulmonary Complications
https://www.aafp.org/afp/2019/1015/p499.html
American Family Physician;

Oct 14th, 2019 - The incidence of pulmonary complications following major surgery is estimated to be 1% to 23%, with the risk varying based on patient factors and the type of surgery.1 Postoperative pulmonary complications include pneumonia, tracheobronchitis, pulmonary edema, pulmonary embolism, atelectasis, pleural effusion, pneumothorax, bronchospasm, aspiration, respiratory failure, and acute respiratory di...

High Expression of DOCK2 Indicates Good Prognosis in AML
https://www.jcancer.org/v10p6088.htm
Journal of Cancer; Hu N, et al

Oct 14th, 2019 - DOCK family proteins are evolutionarily conserved guanine nucleotide exchange factors for Rho GTPase with different cellular functions. It has been demonstrated that DOCK1 had adverse prognostic effect in acute myeloid leukemia (AML).

Esophageal Cancer Treatment (Adult) (PDQ®)–Health Professional Version
https://www.cancer.gov/types/esophageal/hp/adult/esophageal-treatment-pdq

Oct 10th, 2019 - Two histologic types account for the majority of malignant esophageal neoplasms: adenocarcinoma and squamous cell carcinoma. Adenocarcinomas typically start in the lower esophagus and squamous cell carcinoma can develop throughout the esophagus. The epidemiology of these types varies markedly.

Recent Trends in the Treatment and Prognosis of Male Breast Cancer
https://ascopost.com/news/october-2019/recent-trends-in-the-treatment-and-prognosis-of-male-breast-cancer/

Oct 8th, 2019 - A recent analysis published by Yadav et al in Cancer reviewed how the treatment of male breast cancer has evolved over the years 2004 to 2014. In addition, certain patient-, tumor-, and treatment-related factors were found to be linked with better survival.

FDA approves first treatment to increase pain-free light exposure in patients with a rare disorder
https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-increase-pain-free-light-exposure-patients-rare-disorder

Oct 7th, 2019 - The U.S. Food and Drug Administration today granted approval to Scenesse (afamelanotide) to increase pain-free light exposure in adult patients with a history of phototoxic reactions (damage to skin) from erythropoietic protoporphyria.

Novartis receives FDA approval for Beovu®, offering wet AMD patients vision gains and greater fluid reductions vs aflibercept
https://www.novartis.com/news/media-releases/novartis-receives-fda-approval-beovu-offering-wet-amd-patients-vision-gains-and-greater-fluid-reductions-vs-aflibercept

Oct 7th, 2019 - Novartis today announced that the U.S. Food and Drug Administration (FDA) approved Beovu® (brolucizumab) injection, also known as RTH258 for the treatment of wet age-related macular degeneration (AMD)[1]. Beovu is the first FDA approved anti-VEGF to offer both greater fluid resolution versus aflibercept and the ability to maintain eligible wet AMD patients on a three-month dosing interval immed...

Three Leading National Public Health Organizations Ring The Alarm About All-time Highs Of STDs
http://www.ncsddc.org/three-leading-national-public-health-organizations-ring-the-alarm-about-all-time-highs-of-stds/

Oct 7th, 2019 - Data released this week by the Centers for Disease Control and Prevention (CDC) show STDs have surged for the fifth consecutive year, reaching an all-time high in the U.S. These dangerous trends in chlamydia, gonorrhea, and syphilis show no sign of slowing and affect millions of lives each year in the United States. Particularly worrisome is the emerging trend of newborn syphilis (congenital sy...

Cannabis and cannabinoids for people with multiple sclerosis
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013444/full

Oct 6th, 2019 - This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To assess benefit and safety of cannabis‐based medicines, including synthetic, or herbal and plant‐derived cannabinoids, for people with MS.

National Update on Measles Cases and Outbreaks — United States, January 1–October 1, 2019
https://www.cdc.gov/mmwr/volumes/68/wr/mm6840e2.htm
Morbidity and Mortality Weekly Report; Patel, M. et. al.

Oct 3rd, 2019 - What is already known about this topic? Measles was eliminated in the United States in 2000. High national coverage with measles, mumps, and rubella vaccine and rapid implementation of measles control measures prevent widespread measles transmission. What is added by this report? During January–September 2019, 1,249 U.S. measles cases were reported, the highest annual number since 1992...

Hand-Foot-and-Mouth Disease: Rapid Evidence Review
https://www.aafp.org/afp/2019/1001/p408.html
American Family Physician; Saguil, A. et. al.

Sep 30th, 2019 - Hand-foot-and-mouth disease is caused by human enteroviruses and coxsackieviruses. Outbreaks can occur in the spring to fall and are common in North America, and most cases occur in patients younger than 10 years. Hand-foot-and-mouth disease is transmitted by fecal-oral, oral-oral, and respiratory droplet contact. Patients present with a low-grade fever, a maculopapular or papulovesicular rash ...

Protein Oxidation Biomarkers & Myeloperoxidase Activation in Cerebrospinal Fluid in Childhood Bacterial Meningitis
https://www.ncbi.nlm.nih.gov/pubmed/31581487
Antioxidants (Basel); Rugemalira E, et al

Sep 30th, 2019 - The immunological response in bacterial meningitis (BM) causes the formation of reactive oxygen and nitrogen species (ROS, RNS) and activates myeloperoxidase (MPO), an inflammatory enzyme. Thus, structural oxidative and nitrosative damage to proteins and DNA occurs. We aimed to asses these events in the cerebrospinal fluid (CSF) of pediatric BM patients.

FDA approves first treatment for children with rare diseases that cause inflammation of small blood vessels
https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-children-rare-diseases-cause-inflammation-small-blood-vessels

Sep 26th, 2019 - The U.S. Food and Drug Administration today approved Rituxan (rituximab) injection to treat granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in children 2 years of age and older in combination with glucocorticoids (steroid hormones). It is the first approved treatment for children with these rare vasculitis diseases, in which a patient’s small blood vessels become infla...

FDA approves daratumumab for transplant-eligible multiple myeloma
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daratumumab-transplant-eligible-multiple-myeloma

Sep 25th, 2019 - On September 26, 2019, the Food and Drug Administration approved daratumumab (DARZALEX, Janssen) for adult patients with multiple myeloma in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant (ASCT).

Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Health Professional Version
https://www.cancer.gov/types/pheochromocytoma/hp/pheochromocytoma-treatment-pdq

Sep 24th, 2019 - Pheochromocytoma and paraganglioma treatment is usually surgery, however, preoperative medical preparation is critical. Palliative care for metastatic disease may include chemotherapy, radiation therapy, targeted therapy, and other modalities. Get detailed information in this clinician summary.

Malignant Mesothelioma Treatment (Adult) (PDQ®)–Health Professional Version
https://www.cancer.gov/types/mesothelioma/hp/mesothelioma-treatment-pdq

Sep 24th, 2019 - Malignant mesothelioma treatment may include surgery, radiation therapy, and chemotherapy. Get detailed information about the diagnosis and treatment of newly diagnosed and recurrent malignant mesothelioma in this summary for clinicians.

Thymoma and Thymic Carcinoma Treatment (Adult) (PDQ®)–Health Professional Version
https://www.cancer.gov/types/thymoma/hp/thymoma-treatment-pdq

Sep 24th, 2019 - Thymoma and thymic carcinoma treatment options include surgery, radiation therapy, chemotherapy, chemoradiation, and corticosteroids. Get detailed information about treatment of newly diagnosed and recurrent thymoma and thymic cancer in this summary for clinicians.

Screening and Management of the Hyperandrogenic Adolescent
https://www.acog.org/Clinical-Guidance-and-Publications/Committee-Opinions/Committee-on-Adolescent-Health-Care/Screening-and-Management-of-the-Hyperandrogenic-Adolescent

Sep 23rd, 2019 - Although androgen excess can manifest in many ways, the most common and recognizable symptoms are hirsutism and acne. Reports of hirsutism and acne should be taken seriously because of their possible association with medical disorders, their substantial effect on self-esteem and quality of life, and the potential for psychosocial morbidity. In patients with symptoms of androgen excess, the diff...

FDA approves first live, non-replicating vaccine to prevent smallpox and monkeypox
https://www.fda.gov/news-events/press-announcements/fda-approves-first-live-non-replicating-vaccine-prevent-smallpox-and-monkeypox

Sep 23rd, 2019 - The U.S. Food and Drug Administration announced today the approval of Jynneos Smallpox and Monkeypox Vaccine, Live, Non-Replicating, for the prevention of smallpox and monkeypox disease in adults 18 years of age and older determined to be at high risk for smallpox or monkeypox infection. This is the only currently FDA-approved vaccine for the prevention of monkeypox disease.